Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05074940 · OUTCOME

Progression Free Survival -Measured as Time of Treatment Allocation to Confirmed Progressive Disease or Death.

Amivantamab in Adenoid Cystic Carcinoma · Source last updated 2026-05-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 27 months

What was measured

To determine the progression free survival with recurrent and metastatic adenoid cystic carcinoma treated with amivantamab.

Analysis population: 3 patients were unevaluable and excluded from efficacy analyses for discontinuing amivantamab treatment before first restaging. Thus, 18 subjects were included for analyses.

Groups in this outcome

Amivantamab

Amivantamab weekly for the first cycle and biweekly thereafter. Amivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Amivantamab18

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Amivantamab4.6Not reported1.97.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.9
        upper Limit
        7.8
        value
        4.6
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
description
To determine the progression free survival with recurrent and metastatic adenoid cystic carcinoma treated with amivantamab.
dispersion Type
95% Confidence Interval
groups
  1. description
    Amivantamab weekly for the first cycle and biweekly thereafter. Amivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).
    id
    OG000
    title
    Amivantamab
param Type
MEDIAN
population Description
3 patients were unevaluable and excluded from efficacy analyses for discontinuing amivantamab treatment before first restaging. Thus, 18 subjects were included for analyses.
reporting Status
POSTED
time Frame
Up to 27 months
title
Progression Free Survival -Measured as Time of Treatment Allocation to Confirmed Progressive Disease or Death.
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice